Portfolio Cross-sell Benvenue's portfolio includes Kiva VCF (launched 2014) with a cylindrical polymer implant and bone cement reservoir, Luna XD (2020), and Orbit Discectomy Instrumentation (2020). This lets sales teams offer a near-term MIS spine package to the same surgeons and centers, increasing average order value. Target accounts that currently use one product to adopt complementary systems for broader MIS procedures.

Acquisition Synergy Spinal Elements acquired Benvenue's assets in December 2020, suggesting an opportunity to leverage Spinal Elements’ sales channels and customer base. Re-engage dormant or previously served accounts, and explore co-marketing or co-selling arrangements to accelerate field adoption of the combined MIS spine portfolio.

Mid-market Focus With 51-200 employees and revenue under 10M, Benvenue sits in the mid-market spine tech segment. Target mid-sized hospitals and surgical centers that seek nimble, innovative MIS solutions with scalable procurement. Emphasize modular tools and faster onboarding to win multi-site contracts.

Differentiation Edge Kiva VCF uses a proprietary cylindrical polymer implant and a reservoir to guide bone cement flow, providing predictable vertebral support. Orbit Discectomy Instrumentation extends a circumferential discectomy and endplate prep capability to support fusion.

Growth & Funding Benvenue is privately held with funding and has achieved product milestones (Kiva VCF, Luna XD, Orbit). The funding profile supports expansion efforts, clinical trials, and larger-scale deployments across hospitals.